Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Fujian Shengdi Pharmaceutical Co., Ltd.: GMP Innovative Pharmaceutical Factory

Release time：2024-09-29 23:32:03 Source：DuHao

Contact Us Today

Tel : +86-0592-6535000

Email: net.fei@163.com

Address: No. 53, 1st Floor, Building A19, Xiamen Biomedical Industrial Park, No. 2036, Wengjiao West Road, Haicang District, Xiamen, Fujian Province, China

Fujian Shengdi Pharmaceutical Co., Ltd. is a prominent subsidiary of Jiangsu Hengrui Medicine Co., Ltd., a leading pharmaceutical company in China. With a registered capital of RMB 400 million, Fujian Shengdi operates as a key R&D and production base for Hengrui Medicine in South China, focusing on the development and production of small molecule drugs, peptide drugs, special infusion products, and new nucleic acid drugs.

Company Background

Fujian Shengdi is part of the larger Hengrui Medicine group, which was founded in 1970. Over the decades, Hengrui has established itself as an international pharmaceutical leader, known for its high-quality, innovative drugs in the fields of oncology, surgical medicines, contrast agents, and infusion products. With its dual-wheel strategy of innovation and internationalization, Hengrui has successfully launched 11 innovative drugs in China and is currently developing over 60 more. The company is also conducting international clinical trials for nearly 20 drug projects, affirming its global standing.

In 2022, Hengrui ranked 16th in the Global Pharmaceutical R&D TOP 25 list by Informa Pharma Intelligence, and 32nd in the Global Pharmaceutical TOP 50 list by American Pharmaceutical Manager magazine, marking the highest position achieved by a Chinese pharmaceutical company.

Key Operations in Xiamen

Fujian Shengdi, based in Xiamen, Fujian Province, plays a pivotal role in the production and research of innovative drugs and special infusions, particularly in areas such as anti-infection and surgical anesthesia. The company has built a comprehensive drug innovation and production system with two fully operational workshops: a freeze-dried injection workshop and a large-volume soft bag infusion workshop, both of which are supported by state-of-the-art engineering, laboratory, and warehousing facilities. Notably, the freeze-drying workshop passed the GMP compliance inspection and began production in June 2021.

The company is home to more than 200 employees, with over 100 people dedicated to R&D. This team includes over 10 PhDs and 60 Master's degree holders, all contributing to the development of cutting-edge pharmaceuticals. Fujian Shengdi has also established strong academic partnerships with prestigious institutions such as Xiamen University, Huaqiao University, and Xiamen Medical College to cultivate talent in pharmaceutical R&D and production.

Achievements and Future Outlook

In 2021, Fujian Shengdi achieved impressive results, with a revenue of RMB 500 million and over RMB 23 million in tax contributions. For 2022, the company aimed to double its revenue to RMB 1 billion. The company's R&D pipeline includes six clinical trials of innovative drugs, one clinical trial of improved new drugs, and multiple applications for generic drugs. One of its flagship products is the large-volume infusion product, Meilingge.

Looking ahead, Fujian Shengdi is actively expanding its capabilities, particularly with the construction of a high-end Active Pharmaceutical Ingredient (API) base in Xiamen's Haicang District. The project, which covers 94,200 square meters, began in December 2022 and is expected to be fully completed by 2027. The first phase, including a small nucleic acid workshop, is planned to be operational by June 2025.

This expansion will significantly enhance the company's production capacity and solidify its position as a major player in the biopharmaceutical industry in Xiamen. Fujian Shengdi is poised to become one of the top chemical drug production bases for Hengrui Medicine, contributing to its continued growth and success.

Vision and Strategic Goals

Fujian Shengdi's vision is to become a leading innovative pharmaceutical company in South China. By combining research, innovation, and strategic development, the company is building a robust new drug development technology platform. Fujian Shengdi is committed to the transformation and commercialization of its innovative drugs, ensuring it remains at the forefront of pharmaceutical advancements.

As a subsidiary of Hengrui Medicine, Fujian Shengdi's ongoing projects, including its new headquarters and R&D center, are designed to further solidify its role as a key player in both the domestic and international pharmaceutical markets.

DuHao Net